Quantitative MR Measurements of Mean Diffusivity in Glioblastoma Patients with Tumor Treating Fields Plus Standard Therapy versus Standard Treatment Alone

被引：1
|
作者：
Vymazal, J. [1 ]
Zacek, R. [1 ]
Sroubek, J. [1 ]
Klener, J. [1 ]
Rulseh, A. M. [1 ]
机构：
[1] Na Homolce Hosp, Prague, Czech Republic
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2018年 / 102卷 / 03期
关键词：
D O I：
10.1016/j.ijrobp.2018.07.1100
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO_41_2857
引用
收藏
页码：E367 / E367
页数：1
相关论文
共 50 条
  • [1] Quantitative MR measurements in glioblastoma patients: Mean diffusivity with tumor treating fields plus standard therapy versus standard treatment alone
    Vymazal, Josef
    Zacek, Radovan
    Sroubek, Jan
    Klener, Jan
    Rulseh, Aaron M.
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [2] QUANTITATIVE MR MEASUREMENTS IN GLIOBLASTOMA PATIENTS: DIFFERENCE IN MEAN DIFFUSIVITY BETWEEN OPTUNE PATIENTS AND PATIENTS WITH ONLY STANDARD TREATMENT
    Vymazal, Josef
    Zacek, Radovan
    Sroubek, Jan
    Klener, Jan
    Rulseh, Aaron
    [J]. NEURO-ONCOLOGY, 2017, 19 : 143 - 143
  • [3] Overall survival of glioblastoma patients treated by standard therapy in comparison to standard therapy plus tumor treating fields
    Rulseh, Aaron
    Derner, Adam
    Sroubek, Jan
    Klener, Jan
    Vymazal, Josef
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [4] OVERALL SURVIVAL OF NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED BY STANDARD THERAPY IN COMPARISON TO STANDARD THERAPY PLUS TUMOR TREATING FIELDS
    Rulseh, Aaron
    Derner, Adam
    Sroubek, Jan
    Klener, Jan
    Vymazal, Josef
    [J]. NEURO-ONCOLOGY, 2020, 22 : 59 - 59
  • [5] Tumor treating fields: a new standard treatment for glioblastoma?
    Taillibert, Sophie
    Le Rhun, Emilie
    Chamberlain, Marc C.
    [J]. CURRENT OPINION IN NEUROLOGY, 2015, 28 (06) : 659 - 664
  • [6] TUMOR-TREATING FIELDS THERAPY IS COMPATIBLE WITH STANDARD CHEMORADIOTHERAPY FOR GLIOBLASTOMA
    Stachelek, Gregory
    Grimm, Jimm
    Lim, Michael
    Bettegowda, Chetan
    Redmond, Kristin
    Kleinberg, Lawrence
    [J]. NEURO-ONCOLOGY, 2018, 20 : 228 - 228
  • [7] COST EFFECTIVENESS OF TREATING GLIOBLASTOMA PATIENTS AGE 65 YEARS OR OLDER WITH TUMOR TREATING FIELDS PLUS TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE
    Guzauskas, Gregory
    Wang, Bruce C. M.
    Pollom, Erqi
    Stieber, Volker W.
    Garrison, Lou
    [J]. NEURO-ONCOLOGY, 2018, 20 : 116 - 117
  • [8] COST EFFECTIVENESS OF TREATING GLIOBLASTOMA PATIENTS AGE 65 YEARS OR OLDER WITH TUMOR TREATING FIELDS PLUS TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE
    Guzauskas, G. F.
    Wang, B. C. M.
    Pollom, E. L.
    Stieber, V. W.
    Kinzel, A.
    Proescholdt, C.
    Garrison, L.
    [J]. NEURO-ONCOLOGY, 2018, 20 : 254 - 254
  • [9] COST-EFFECTIVE ANALYSIS FOR SIMVASTATIN PLUS STANDARD THERAPY VERSUS STANDARD THERAPY ALONE IN CRITICALLY ILL SEPTIC PATIENTS
    Eladawy, S.
    Bazan, N. S.
    Elgendy, M. A. A.
    Zaki, M. A.
    [J]. VALUE IN HEALTH, 2019, 22 : S375 - S375
  • [10] COST PER SUCCESSFUL RESPONSE OF STANDARD TREATMENT PLUS CINACALCET VERSUS STANDARD TREATMENT ALONE IN PATIENTS WITH SECONDARY HYPERPARATHYROIDISM IN MEXICO
    Arocho, R.
    Ianazzo, S.
    Rivera Hurtado, R.
    Paniagua Sierra, J. R.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A570 - A570
12345